» Articles » PMID: 29244227

Surveillance for Hepatobiliary Cancers in Patients with Primary Sclerosing Cholangitis

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2017 Dec 16
PMID 29244227
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Conclusion: This study demonstrates that HBCa surveillance significantly improves outcomes, including survival, in patients with PSC. (Hepatology 2018;67:2338-2351).

Citing Articles

Primary sclerosing cholangitis.

Manns M, Bergquist A, Karlsen T, Levy C, Muir A, Ponsioen C Nat Rev Dis Primers. 2025; 11(1):17.

PMID: 40082445 DOI: 10.1038/s41572-025-00600-x.


Treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis: a comprehensive review.

Villard C, Jorns C, Bergquist A eGastroenterology. 2025; 2(1):e100045.

PMID: 39944751 PMC: 11770459. DOI: 10.1136/egastro-2023-100045.


Management of primary sclerosing cholangitis: Current state-of-the-art.

Cancado G, Hirschfield G Hepatol Commun. 2025; 8(12).

PMID: 39774274 PMC: 11567710. DOI: 10.1097/HC9.0000000000000590.


Gut Microbiome and Bile Acid Interactions: Mechanistic Implications for Cholangiocarcinoma Development, Immune Resistance, and Therapy.

Wu N, Bayatpour S, Hylemon P, Aseem S, Aseem S, Brindley P Am J Pathol. 2024; 195(3):397-408.

PMID: 39730075 PMC: 11841492. DOI: 10.1016/j.ajpath.2024.11.004.


Past, current, and future trends in the prevalence of primary sclerosing cholangitis and inflammatory bowel disease across England (2015-2027): a nationwide, population-based study.

Crothers H, Ferguson J, Quraishi M, Cooney R, Iqbal T, Trivedi P Lancet Reg Health Eur. 2024; 44:101002.

PMID: 39099647 PMC: 11296053. DOI: 10.1016/j.lanepe.2024.101002.